![Vivek Subbiah, MD on X: "🚨Today FDA approved a drug nab-sirolimus for an ultra rare sarcoma- a unicorn🦄 -PECOMA. 👉🏼Sarcomas are more than 150 different types. 👉🏼Time to identify targets & drugs Vivek Subbiah, MD on X: "🚨Today FDA approved a drug nab-sirolimus for an ultra rare sarcoma- a unicorn🦄 -PECOMA. 👉🏼Sarcomas are more than 150 different types. 👉🏼Time to identify targets & drugs](https://pbs.twimg.com/media/FE4sU8jXMAknTLe.jpg)
Vivek Subbiah, MD on X: "🚨Today FDA approved a drug nab-sirolimus for an ultra rare sarcoma- a unicorn🦄 -PECOMA. 👉🏼Sarcomas are more than 150 different types. 👉🏼Time to identify targets & drugs
![nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.21.01728/asset/images/large/jco.21.01728t1.jpeg)
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology
ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and M
ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and M
![nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.21.01728/asset/images/large/jco.21.01728f2.jpeg)
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology
![A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report | Diagnostic Pathology | Full Text A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report | Diagnostic Pathology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13000-023-01323-x/MediaObjects/13000_2023_1323_Fig1_HTML.png)
A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report | Diagnostic Pathology | Full Text
![Malignant tumors of the PEComa family. A. As per definition, malignant... | Download Scientific Diagram Malignant tumors of the PEComa family. A. As per definition, malignant... | Download Scientific Diagram](https://www.researchgate.net/publication/339625221/figure/fig1/AS:864629370667011@1583155114369/Malignant-tumors-of-the-PEComa-family-A-As-per-definition-malignant-PEComas-is.png)
Malignant tumors of the PEComa family. A. As per definition, malignant... | Download Scientific Diagram
![PEComa histology and immunohistochemistry (IHC). (A) Representative... | Download Scientific Diagram PEComa histology and immunohistochemistry (IHC). (A) Representative... | Download Scientific Diagram](https://www.researchgate.net/publication/346886445/figure/fig1/AS:11431281181671184@1692135603385/PEComa-histology-and-immunohistochemistry-IHC-A-Representative-image-of-the.png)
PEComa histology and immunohistochemistry (IHC). (A) Representative... | Download Scientific Diagram
![Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa | Business Wire Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa | Business Wire](https://mms.businesswire.com/media/20190603005173/en/724790/23/AADi_High_resolution_logo.jpg)
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa | Business Wire
![Targeted Oncology on X: "FDA approval has been granted to nab-sirolimus for intravenous use as treatment of patients with advanced malignant perivascular epithelioid cell tumors. READ MORE: https://t.co/byWBqVgF38 https://t.co/CN8RVCpeCG" / X Targeted Oncology on X: "FDA approval has been granted to nab-sirolimus for intravenous use as treatment of patients with advanced malignant perivascular epithelioid cell tumors. READ MORE: https://t.co/byWBqVgF38 https://t.co/CN8RVCpeCG" / X](https://pbs.twimg.com/media/FFIpdh2XEBU41aM.jpg)
Targeted Oncology on X: "FDA approval has been granted to nab-sirolimus for intravenous use as treatment of patients with advanced malignant perivascular epithelioid cell tumors. READ MORE: https://t.co/byWBqVgF38 https://t.co/CN8RVCpeCG" / X
![Frontiers | Uterine collision tumor (PEComa and endometrioid carcinoma) in a tuberous sclerosis patient: a case report Frontiers | Uterine collision tumor (PEComa and endometrioid carcinoma) in a tuberous sclerosis patient: a case report](https://www.frontiersin.org/files/Articles/1244261/fonc-13-1244261-HTML/image_m/fonc-13-1244261-g001.jpg)
Frontiers | Uterine collision tumor (PEComa and endometrioid carcinoma) in a tuberous sclerosis patient: a case report
![nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2021/jco.2021.39.issue-33/jco.21.01728/20231020/images/keyimage.jpg)
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology
![nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.21.01728/asset/images/large/jco.21.01728t2.jpeg)
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors | Journal of Clinical Oncology
![Estimating Aadi Biosciences' (AADI) chances of success for tumor agnostic approval in malignant solid tumors with pathogenic TSC1 or TSC2 inactivating alterations. Estimating Aadi Biosciences' (AADI) chances of success for tumor agnostic approval in malignant solid tumors with pathogenic TSC1 or TSC2 inactivating alterations.](https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd2e4a10b-20d1-4fe3-a497-6729dba0eed1_2540x1430.png)
Estimating Aadi Biosciences' (AADI) chances of success for tumor agnostic approval in malignant solid tumors with pathogenic TSC1 or TSC2 inactivating alterations.
![Albumin-bağlı Rapamisin (nab-sirolimus) Amerika Birleşik Devletleri'nde Listelenmek İçin Uygulandı! - Sektörel Haberler - Haberler - Hefei Home Sunshine İlaç Teknolojisi Co, Ltd Albumin-bağlı Rapamisin (nab-sirolimus) Amerika Birleşik Devletleri'nde Listelenmek İçin Uygulandı! - Sektörel Haberler - Haberler - Hefei Home Sunshine İlaç Teknolojisi Co, Ltd](http://tr.hsp-pharma.com/Content/uploads/2020524038/20200709173311e177f5eb432d4683aaa2d54890a433bf.png)